The Bulletin
Times Advertising


.

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

  • Written by PR Newswire
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspensi...

The Bulletin Magazine

THE BENEFITS OF A BUILDING AND PEST INSPECTION

A LOOK INTO PROPERTY INSPECTION: WHAT ACTUALLY QUALIFIES AS PROFESSIONAL

How to choose the right timber decking for your home or project

What to look for in disability services: a practical guide for NDIS participants and their families

Who Should Consider Mole Mapping in Melbourne?

Why Buy Carbohydrate Supplements Are Essential For Weight Gain And Bodybuilding Performance

Engineered Timber Floors Melbourne: Creating Timeless And Durable Interiors

Year 12 Tutoring Helping Students Navigate Their Most Important Academic Year

Simple Home Upgrades That Improve Security, Comfort and Everyday Living

What is a Design and Build Contract? A Complete Guide

How Melbourne Homeowners Keep Their Homes Clean Year-Round (Without Spending Their Weekends Doing It)

Why Choosing The Right GP Bundoora Is Key To Long-Term Health Management

hacklink hack forum hacklink film izle hacklink testjetbahisslot gacortipobetRocket Playivermectin tabletiptv satın aliptv satın alcasibomTaraftarium24jojobetgrandpashabetholiganbetkulisbetkulisbetkulisbetkulisbetkulisbettogel onlinegalabetbetofficebetofficedeneme bonusuvirüsbetvirüsbetNon Gamstop Sitesmatbetkingroyalkingroyal